nifedipine has been researched along with Diabetic Angiopathies in 17 studies
Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 9.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| " However, the short-acting formulations of nifedipine had pharmacokinetic properties that were far from ideal and in 1995, several studies involving various dosing regimens reported possible dangerous effects in secondary prevention." | 6.44 | Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension. ( Dunselman, PH; Kragten, JA, 2007) |
| " A total of 54 type 1 diabetic patients with albuminuria and blood pressure (BP) <150/90 mmHg were randomized to receive 10 mg enalapril once daily, 10 mg nifedipine retard twice daily, or placebo in a multicenter double-blind study of 3 years' duration." | 5.09 | Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT). ( , 2001) |
| "To examine the factors that determine the blood pressure response to enalapril and nifedipine monotherapy in the treatment of hypertension associated with non-insulin-dependent diabetes mellitus (NIDDM)." | 5.08 | Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM. ( Chan, JC; Cheung, CK; Cockram, CS; Law, LK; Nicholls, MG; Swaminathan, R, 1995) |
| " Angiotensin converting enzyme inhibitors (ACE-I) significantly retarded the development of end-stage renal failure compared to antihypertensives other than ACE-I (mostly nifedipine), and the effect was evident particularly in patients with proteinuria below the median (2." | 5.08 | Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. ( Babazono, T; Hirayama, M; Ishii, A; Omori, Y; Takahashi, C; Takeda, M; Tomonaga, O; Ujihara, U; Yokoyama, H, 1997) |
| " We, along with others, have recently found that nifedipine, one of the most widely used DHPs, inhibits apoptotic cell death of endothelial cells (ECs) as well as vascular inflammation and subsequently improves endothelial function in patients with cardiovascular risk factors, including hypertension and/or diabetes, thus slowing the development and progression of atherosclerosis in these patients." | 4.84 | Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine. ( Matsui, T; Nakamura, K; Yamagishi, S, 2008) |
| "Hypertensive NIDDM subjects were treated for 3 months with captopril, nifedipine, or doxazosin." | 2.68 | Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment. ( Canessa, ML; Castellino, P; DeFronzo, RA; Giordano, M; Solini, A, 1997) |
| " However, the short-acting formulations of nifedipine had pharmacokinetic properties that were far from ideal and in 1995, several studies involving various dosing regimens reported possible dangerous effects in secondary prevention." | 2.44 | Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension. ( Dunselman, PH; Kragten, JA, 2007) |
| "Does nifedipine treatment alone decrease the progression of renal disease with overt proteinuria? If these answers are yes, are these beneficial effects of nifedipine superior to that of other DHPs with equihypotensive properties? Does nifedipine treatment also reduce oxidative stress markers? Are these unique effects of nifedipine correlated with its anti-oxidative properties? These prospective studies will provide further valuable information whether nifedipine may be a preferred DHP to achieve BP goals in hypertensive patients with systolic dysfunction or overt proteinuria." | 1.34 | Revival of nifedipine, a dihydropyridine-based calcium blocker. ( Nakamura, K; Yamagishi, S, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (11.76) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, LP | 1 |
| Jiang, Y | 1 |
| Yang, H | 1 |
| Peng, C | 1 |
| Zhang, C | 1 |
| Tao, X | 1 |
| Xie, HH | 1 |
| Yamagishi, S | 3 |
| White, WB | 1 |
| Yui, Y | 1 |
| Sumiyoshi, T | 1 |
| Kodama, K | 1 |
| Hirayama, A | 1 |
| Nonogi, H | 1 |
| Kanmatsuse, K | 1 |
| Origasa, H | 1 |
| Iimura, O | 1 |
| Ishii, M | 1 |
| Saruta, T | 1 |
| Arakawa, K | 1 |
| Hosoda, S | 1 |
| Kawai, C | 1 |
| Nakamura, K | 2 |
| Kragten, JA | 1 |
| Dunselman, PH | 1 |
| Matsui, T | 1 |
| Chan, JC | 1 |
| Nicholls, MG | 1 |
| Cheung, CK | 1 |
| Law, LK | 1 |
| Swaminathan, R | 1 |
| Cockram, CS | 1 |
| O'Donnell, MJ | 1 |
| Rowe, BR | 1 |
| Lawson, N | 1 |
| Horton, A | 1 |
| Gyde, OH | 1 |
| Barnett, AH | 1 |
| Crepaldi, G | 1 |
| Carraro, A | 1 |
| Brocco, E | 1 |
| Adezati, L | 1 |
| Andreani, D | 1 |
| Bompiani, G | 1 |
| Brunetti, P | 1 |
| Fedele, D | 1 |
| Giorgino, R | 1 |
| Giustina, G | 1 |
| Yokoyama, H | 1 |
| Tomonaga, O | 1 |
| Hirayama, M | 1 |
| Ishii, A | 1 |
| Takeda, M | 1 |
| Babazono, T | 1 |
| Ujihara, U | 1 |
| Takahashi, C | 1 |
| Omori, Y | 1 |
| Giordano, M | 1 |
| Castellino, P | 1 |
| Solini, A | 1 |
| Canessa, ML | 1 |
| DeFronzo, RA | 1 |
| Orie, NN | 1 |
| Anyaegbu, NO | 1 |
| Pola, P | 1 |
| Savi, L | 1 |
| Kawai, K | 1 |
| Suzuki, S | 1 |
| Murayama, Y | 1 |
| Watanabe, Y | 1 |
| Yamashita, K | 1 |
| Belcaro, G | 1 |
| Nicholaides, AN | 1 |
4 reviews available for nifedipine and Diabetic Angiopathies
| Article | Year |
|---|---|
[Calcium antagonists: current and future applications based on new evidence. Calcium antagonists and diabetes].
Topics: Antioxidants; Calcium Channel Blockers; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Reti | 2010 |
Clinical trial experience around the globe: focus on calcium-channel blockers.
Topics: Amiloride; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as To | 2003 |
Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension.
Topics: Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Coronary Disease; Cost Savings; D | 2007 |
Role of oxidative stress in the development of vascular injury and its therapeutic intervention by nifedipine.
Topics: Antioxidants; Apoptosis; Atherosclerosis; Calcium Channels; Cardiovascular Diseases; Cytokines; Diab | 2008 |
8 trials available for nifedipine and Diabetic Angiopathies
| Article | Year |
|---|---|
Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JM
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Coronary Disease; Dia | 2004 |
Factors determining the blood pressure response to enalapril and nifedipine in hypertension associated with NIDDM.
Topics: Albuminuria; Aldosterone; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Glucose; Blood P | 1995 |
Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: a randomised double-blind study.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 1993 |
Hypertension and non-insulin-dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 1995 |
Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1997 |
Na+/Li+ and Na+/H+ countertransport activity in hypertensive non-insulin-dependent diabetic patients: role of insulin resistance and antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Antiporters; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; D | 1997 |
Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT).
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium | 2001 |
Comparison of the effects of nilvadipine and captopril on glucose and lipid metabolism in NIDDM patients with hypertension.
Topics: Analysis of Variance; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins B; Blood Glucose; Blo | 1992 |
5 other studies available for nifedipine and Diabetic Angiopathies
| Article | Year |
|---|---|
Combination Therapy of Nifedipine and Sulphonylureas Exhibits a Mutual Antagonistic Effect on the Endothelial Cell Dysfunction Induced by Hyperglycemia Linked to Vascular Disease.
Topics: Antihypertensive Agents; Biphenyl Compounds; Cell Movement; Diabetic Angiopathies; Drug Synergism; E | 2016 |
Revival of nifedipine, a dihydropyridine-based calcium blocker.
Topics: Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Diabet | 2007 |
Nifedipine effectively lowers salt-induced high blood pressure in diabetic rats.
Topics: Animals; Blood Pressure; Diabetic Angiopathies; Hypertension; Male; Nifedipine; Norepinephrine; Rats | 1999 |
Peripheral vascular dynamics studied by calcium ion inhibition.
Topics: Adult; Aged; Arteriosclerosis; Calcium; Diabetic Angiopathies; Humans; Middle Aged; Muscle, Smooth; | 1978 |
Microvascular evaluation of the effects of nifedipine in vascular patients by laser-Doppler flowmetry.
Topics: Diabetic Angiopathies; Female; Foot; Humans; Lasers; Male; Microcirculation; Middle Aged; Nifedipine | 1989 |